

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-22 (Canceled).

Claim 23 (Currently Amended): A method for inhibiting the formation of metastases in cancer treatment in a subject comprising the step of administering at least one TGF-beta2 antisense oligonucleotide selected from the group consisting of: SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 48 to a subject, wherein said at least one oligonucleotide inhibits the formation of metastases in said subject.

Claims 24-26 (Canceled).

Claim 27 (Currently Amended): The method of claim 23, wherein said oligonucleotide is identified in the sequence listing under selected from the group consisting of: SEQ ID NOs: SEQ ID NO: 1, 5, 6, 8, 9, 14, 15, 16, 28, 29, [[30,]] 34, 35, [[36,]] 40, and 42.

Claim 28 (Currently Amended): The method of claim 23, wherein said cancer is selected from the group consisting of ~~bile duct carcinoma, bladder carcinoma, brain tumor, breast cancer, bronchogenic carcinoma, carcinoma of the kidney, cervical cancer, chorioecarcinoma, cystadenocarcinoma, cervical carcinoma, colon carcinoma, colorectal carcinoma, embriional carcinoma, endometrial cancer, epithelial carcinoma, esophageal cancer, gallbladder cancer, gastric cancer, head and neck cancer, hepatocellular cancer, liver carcinoma, lung carcinoma, medullary carcinoma, non-small cell bronchogenic/lung carcinoma, ovarian cancer, pancrease pancreas carcinoma, and papillary carcinoma, papillary adenocarcinoma, prostatic cancer, small intestine carcinoma, rectal cancer, renal cell carcinoma, sebaceous gland carcinoma, skin cancer, small cell bronchogenic/lung carcinoma, soft tissue cancer, squamous cell carcinoma, testicular carcinoma, uterine~~

cancer, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; pre-malignant tumors, blastoma, Ewing's tumor, craniopharyngioma, ependymoma, medulloblastoma, hemangioblastoma, medulloblastoma, melanoma, mesothelioma, neuroblastoma, neurofibroma, pinealoma, retinoblastoma, retinoblastoma, sarcoma (including angiosarcoma, chondrosarcoma, endothelial sarcoma, fibrosarcoma, gliosarcoma, leiomyosarcoma, liposarcoma, lymphangioendothelial sarcoma, lymphangiosarcoma, melanoma, meningioma, myosarcoma, osteogenic sarcoma, osteosarcoma), seminoma, trachomas, Wilm's tumor and multiple myeloma.

Claim 29 (Currently Amended): The method of claim 23, wherein said cancer is selected from the group consisting of: ~~prostate prostate~~ cancer, colon carcinoma, endometrial cancer, esophageal cancer, hepatocellular cancer, non-small-cell lung carcinoma, ovarian cancer, and pancreas ~~pancreas~~ carcinoma, soft-tissue cancer, melanoma, renal cancer, leukaemia, lymphoma, osteosarcoma, mesothelioma, myeloma multiple and bladder cancer.

Claim 30 (Currently Amended): A method for cancer treatment comprising the step of administering at least one TGF-beta2 antisense oligonucleotide selected from the group consisting of SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 48 to a subject, wherein said at least one TGF-beta2 antisense oligonucleotide inhibits the formation of metastases in said subject and said cancer is selected from the group consisting of: prostate cancer, ~~bladder carcinoma~~, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, and pancreatic cancer or is selected from the group of melanoma, renal cancer, leukaemia, lymphoma, osteosarcoma, mesothelioma, myeloma multiple and bladder cancer.

Claims 31-33 (Canceled).

Claim 34 (Withdrawn): An antisense-oligonucleotide or its active derivative, selected from the group consisting of IL-10 antisense oligonucleotides identified in the sequence listing under Seq. ID NO. 49 to 68 or identified in example 22.

Claim 35 (Withdrawn): A process of manufacturing an antisense oligonucleotide or its active derivative of claim 12, comprising the step of adding consecutive nucleosides and linker stepwise or cutting said oligonucleotide out of a longer oligonucleotide chain.

Claim 36 (Withdrawn): A process of manufacturing an antisense oligonucleotide or its active derivative by phosphate triester chemistry in which said nucleotide chain grows in 3' to 5' direction and each consecutive nucleotide is coupled to a first nucleotide that is covalently attached to a solid phase, comprising the steps of cleaving the 5' DMT protecting group of each consecutive nucleotide adding a consecutive nucleotide for chain prolongation, modifying phosphate groups, capping unreacted 5'-hydroxyl groups, cleaving said oligonucleotides from said solid support.

Claim 37 (Withdrawn): The process of claim 36, comprising the further step of working up the synthesis product.

Claim 38 (Withdrawn): A Pharmaceutical composition comprising an antisense oligonucleotide as identified in the sequence listing under Seq. ID NO 49 to 68 or as identified in example 22.

Claims 39-43 (Canceled).

Claim 44 (Currently Amended): A method for cancer metastasis treatment comprising the step of administering at least one TGF-beta2 antisense oligonucleotide selected from the group consisting of: SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 48 to a subject, wherein said cancer is selected from the group consisting of colon cancer, prostate cancer, and pancreatic cancer melanoma, bladder cancer, endometrial cancer, esophageal cancer, hepatocellular cancer,

~~non-small-cell lung cancer, ovarian cancer, osteosarcoma, mesothelioma, renal cancer, myeloma multiple, pancreas carcinoma, leukaemia, lymphoma and soft tissue cancer.~~

Claim 45 (Withdrawn): The method of claim 44, wherein said at least one antisense oligonucleotide is identified in the sequence listing under SEQ ID NO 49 to 69 or is identified in example 22.